SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
12/26/2025 10:47 AM • Law firm Faruqi & Faruqi is investigating potential securities fraud claims against Skye Bioscience following the company's announcement that its drug nimacimab failed to meet primary endpoints in a Phase 2a clinical trial. The disclosure of lower-than-expected drug exposure and failure to achieve weight loss compared to placebo resulted in a 60% stock price decline on October 6, 2025. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to contact the firm, with a January 16, 2026 deadline to seek lead plaintiff status.
SKYE - The company faces securities litigation alleging false and misleading statements about its drug candidate nimacimab's effectiveness. The clinical trial failure resulted in a 60% stock price drop, and executives are accused of overstating the drug's clinical, regulatory, and commercial prospects.
Investing.com • Thomas Hughes